{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,19]],"date-time":"2025-06-19T17:25:50Z","timestamp":1750353950477,"version":"3.37.0"},"reference-count":39,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2024,9,1]],"date-time":"2024-09-01T00:00:00Z","timestamp":1725148800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","gynecologiconcology-online.net","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2024,9]]},"DOI":"10.1016\/j.ygyno.2024.05.028","type":"journal-article","created":{"date-parts":[[2024,6,14]],"date-time":"2024-06-14T02:28:11Z","timestamp":1718332091000},"page":"22-26","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer"],"prefix":"10.1016","volume":"188","author":[{"given":"Christopher A.","family":"Walker","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Carson","family":"Edwards","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Don","family":"McIntire","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lydia","family":"Makepeace","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven Blaine","family":"Holloway","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ev","family":"Kakadiaris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alexandra N.","family":"Spirtos","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David S.","family":"Miller","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jayanthi S.","family":"Lea","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"13","key":"10.1016\/j.ygyno.2024.05.028_bb0005","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1182\/blood-2017-03-743211","article-title":"Cancer-associated pathways and biomarkers of venous thrombosis","volume":"130","author":"Hisada","year":"2017","journal-title":"Blood"},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.028_bb0010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1038\/s41572-022-00336-y","article-title":"Cancer-associated venous thromboembolism","volume":"8","author":"Khorana","year":"2022","journal-title":"Nat. Rev. Dis. Primers"},{"issue":"10","key":"10.1016\/j.ygyno.2024.05.028_bb0015","doi-asserted-by":"crossref","first-page":"4902","DOI":"10.1182\/blood-2007-10-116327","article-title":"Development and validation of a predictive model for chemotherapy-associated thrombosis","volume":"111","author":"Khorana","year":"2008","journal-title":"Blood"},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.028_bb0020","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1055\/s-0037-1613051","article-title":"Venous thrombosis in patients with solid tumors: determination of frequency and characteristics","volume":"87","author":"Sallah","year":"2002","journal-title":"Thromb. Haemost."},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.028_bb0025","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1001\/archinte.166.4.458","article-title":"Incidence of venous thromboembolism and its effect on survival among patients with common cancers","volume":"166","author":"Chew","year":"2006","journal-title":"Arch. Intern. Med."},{"issue":"12","key":"10.1016\/j.ygyno.2024.05.028_bb0030","doi-asserted-by":"crossref","first-page":"2822","DOI":"10.1002\/cncr.21496","article-title":"Risk factors for chemotherapy-associated venous thromboembolism in a prospective observational study: risk factors for thrombosis with chemotherapy","volume":"104","author":"Khorana","year":"2005","journal-title":"Cancer"},{"issue":"16","key":"10.1016\/j.ygyno.2024.05.028_bb0035","doi-asserted-by":"crossref","first-page":"2683","DOI":"10.1200\/JCO.2008.16.1109","article-title":"Incidence of venous thromboembolism in patients with ovarian cancer undergoing platinum\/paclitaxel\u2013containing first-line chemotherapy: an exploratory analysis by the arbeitsgemeinschaft gynaekologische onkologie ovarian cancer study group","volume":"26","author":"Fotopoulou","year":"2008","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.028_bb0040","doi-asserted-by":"crossref","first-page":"e127","DOI":"10.1016\/j.thromres.2013.01.027","article-title":"Incidence of venous thromboembolism before treatment in cervical cancer and the impact of management on venous thromboembolism after commencement of treatment","volume":"131","author":"Satoh","year":"2013","journal-title":"Thromb. Res."},{"issue":"3","key":"10.1016\/j.ygyno.2024.05.028_bb0045","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1016\/j.ygyno.2016.06.012","article-title":"Significance of venous thromboembolism in women with cervical cancer","volume":"142","author":"Matsuo","year":"2016","journal-title":"Gynecol. Oncol."},{"issue":"10","key":"10.1016\/j.ygyno.2024.05.028_bb0050","doi-asserted-by":"crossref","first-page":"2339","DOI":"10.1002\/cncr.23062","article-title":"Frequency, risk factors, and trends for venous thromboembolism among hospitalized cancer patients","volume":"110","author":"Khorana","year":"2007","journal-title":"Cancer"},{"key":"10.1016\/j.ygyno.2024.05.028_bb0055","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.thromres.2023.04.015","article-title":"Apixaban thromboprophylaxis in ambulatory patients with cancer and obesity: insights from the AVERT trial","volume":"226","author":"Potere","year":"2023","journal-title":"Thromb. Res."},{"issue":"5","key":"10.1016\/j.ygyno.2024.05.028_bb0060","doi-asserted-by":"crossref","first-page":"994","DOI":"10.1002\/cncr.20893","article-title":"Prospective evaluation of major vascular events in patients with nonsmall cell lung carcinoma treated with cisplatin and gemcitabine","volume":"103","author":"Numico","year":"2005","journal-title":"Cancer"},{"issue":"35","key":"10.1016\/j.ygyno.2024.05.028_bb0065","doi-asserted-by":"crossref","first-page":"4416","DOI":"10.1200\/JCO.2012.42.4358","article-title":"Risk of venous thromboembolism in patients with cancer treated with cisplatin: a systematic review and Meta-analysis","volume":"30","author":"Seng","year":"2012","journal-title":"JCO"},{"issue":"25","key":"10.1016\/j.ygyno.2024.05.028_bb0070","doi-asserted-by":"crossref","first-page":"3466","DOI":"10.1200\/JCO.2011.35.5669","article-title":"High incidence of thromboembolic events in patients treated with cisplatin-based chemotherapy: a large retrospective analysis","volume":"29","author":"Moore","year":"2011","journal-title":"JCO"},{"issue":"4","key":"10.1016\/j.ygyno.2024.05.028_bb0075","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.medj.2021.02.002","article-title":"Increased incidence of venous thromboembolism with cancer immunotherapy","volume":"2","author":"Roopkumar","year":"2021","journal-title":"Med"},{"issue":"28","key":"10.1016\/j.ygyno.2024.05.028_bb0080","doi-asserted-by":"crossref","first-page":"4649","DOI":"10.1200\/JCO.2009.21.8909","article-title":"Phase III trial of four cisplatin-containing doublet combinations in stage IVB, recurrent, or persistent cervical carcinoma: a gynecologic oncology group study","volume":"27","author":"Monk","year":"2009","journal-title":"JCO"},{"issue":"10103","key":"10.1016\/j.ygyno.2024.05.028_bb0085","doi-asserted-by":"crossref","first-page":"1654","DOI":"10.1016\/S0140-6736(17)31607-0","article-title":"Bevacizumab for advanced cervical cancer: final overall survival and adverse event analysis of a randomised, controlled, open-label, phase 3 trial (gynecologic oncology group 240)","volume":"390","author":"Tewari","year":"2017","journal-title":"Lancet"},{"issue":"20","key":"10.1016\/j.ygyno.2024.05.028_bb0090","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N. Engl. J. Med."},{"issue":"24","key":"10.1016\/j.ygyno.2024.05.028_bb0095","doi-asserted-by":"crossref","first-page":"5377","DOI":"10.1182\/blood-2010-02-270116","article-title":"Prediction of venous thromboembolism in cancer patients","volume":"116","author":"Ay","year":"2010","journal-title":"Blood"},{"issue":"3","key":"10.1016\/j.ygyno.2024.05.028_bb0100","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1007\/s11739-012-0784-y","article-title":"A modified Khorana risk assessment score for venous thromboembolism in cancer patients receiving chemotherapy: the Protecht score","volume":"7","author":"Verso","year":"2012","journal-title":"Intern. Emerg. Med."},{"issue":"10","key":"10.1016\/j.ygyno.2024.05.028_bb0105","doi-asserted-by":"crossref","first-page":"1222","DOI":"10.1634\/theoncologist.2016-0414","article-title":"A predictive score for thrombosis associated with breast, colorectal, lung, or ovarian cancer: the prospective COMPASS\u2013cancer-associated thrombosis study","volume":"22","author":"Gerotziafas","year":"2017","journal-title":"Oncologist"},{"key":"10.1016\/j.ygyno.2024.05.028_bb0110","article-title":"Use of the Khorana score to predict venous thromboembolism in patients undergoing chemotherapy for uterine cancer","volume":"46","author":"Piver","year":"2023","journal-title":"Gynecol. Oncol. Rep."},{"key":"10.1016\/j.ygyno.2024.05.028_bb0115","doi-asserted-by":"crossref","first-page":"S288","DOI":"10.1016\/S0090-8258(21)01200-2","article-title":"The clinical utility of the Khorana score in determining risk for venous thromboembolism in patients with gynecologic cancer","volume":"162","author":"Apple","year":"2021","journal-title":"Gynecol. Oncol."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.028_bb0120","doi-asserted-by":"crossref","first-page":"307","DOI":"10.1182\/bloodadvances.2021005590","article-title":"The incidence of cancer-associated thrombosis is increasing over time","volume":"6","author":"Mahajan","year":"2022","journal-title":"Blood Adv."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.028_bb0125","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1006\/gyno.2001.6452","article-title":"The clinical course of deep vein thrombosis in patients with gynecologic cancer","volume":"84","author":"Morgan","year":"2002","journal-title":"Gynecol. Oncol."},{"issue":"3","key":"10.1016\/j.ygyno.2024.05.028_bb0130","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1111\/j.1538-7836.2007.02374.x","article-title":"Thromboembolism is a leading cause of death in cancer patients receiving outpatient chemotherapy","volume":"5","author":"Khorana","year":"2007","journal-title":"J. Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.028_bb0135","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1016\/S1470-2045(07)70409-6","article-title":"Venous thromboembolism in cervical cancer","volume":"9","author":"Barbera","year":"2008","journal-title":"Lancet Oncol."},{"issue":"13","key":"10.1016\/j.ygyno.2024.05.028_bb0140","doi-asserted-by":"crossref","first-page":"1757","DOI":"10.1200\/JCO.2010.32.3220","article-title":"Venous thromboembolic events with chemotherapy plus bevacizumab: a pooled analysis of patients in randomized phase II and III studies","volume":"29","author":"Hurwitz","year":"2011","journal-title":"JCO"},{"issue":"3","key":"10.1016\/j.ygyno.2024.05.028_bb0145","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1002\/cncr.27772","article-title":"Incidence and predictors of venous thromboembolism (VTE) among ambulatory high-risk cancer patients undergoing chemotherapy in the United States: VTE in ambulatory US cancer patients","volume":"119","author":"Khorana","year":"2013","journal-title":"Cancer"},{"issue":"19","key":"10.1016\/j.ygyno.2024.05.028_bb0150","doi-asserted-by":"crossref","first-page":"2277","DOI":"10.1001\/jama.2008.656","article-title":"Risk of venous thromboembolism with the angiogenesis inhibitor bevacizumab in cancer patients: a meta-analysis","volume":"300","author":"Nalluri","year":"2008","journal-title":"JAMA"},{"issue":"18","key":"10.1016\/j.ygyno.2024.05.028_bb0155","doi-asserted-by":"crossref","first-page":"4603","DOI":"10.3390\/cancers13184603","article-title":"Risk of thrombo-embolic events in ovarian cancer: does bevacizumab tilt the scale? A systematic review and meta-analysis","volume":"13","author":"Saerens","year":"2021","journal-title":"Cancers"},{"issue":"14","key":"10.1016\/j.ygyno.2024.05.028_bb0160","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1182\/blood.2020007338","article-title":"Venous thromboembolism in cancer patients: a population-based cohort study","volume":"137","author":"Mulder","year":"2021","journal-title":"Blood"},{"issue":"16","key":"10.1016\/j.ygyno.2024.05.028_bb0165","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1200\/JCO.23.00294","article-title":"Venous thromboembolism prophylaxis and treatment in patients with cancer: ASCO guideline update","volume":"41","author":"Key","year":"2023","journal-title":"JCO"},{"issue":"Supplement_1","key":"10.1016\/j.ygyno.2024.05.028_bb0170","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1182\/blood-2019-128831","article-title":"Bleeding risk in a cohort of ambulatory cancer patients receiving outpatient prophylactic anticoagulation for venous thrombosis prevention","volume":"134","author":"Wilks","year":"2019","journal-title":"Blood"},{"issue":"Supplement_1","key":"10.1016\/j.ygyno.2024.05.028_bb0175","doi-asserted-by":"crossref","first-page":"4669","DOI":"10.1182\/blood-2019-127917","article-title":"Meta-analysis and cost-effectiveness analysis of low-dose direct Oral anticoagulant for the prevention of cancer associated thrombosis","volume":"134","author":"Li","year":"2019","journal-title":"Blood"},{"issue":"8","key":"10.1016\/j.ygyno.2024.05.028_bb0180","doi-asserted-by":"crossref","first-page":"1736","DOI":"10.1002\/cncr.32724","article-title":"Cost-effectiveness analysis of low-dose direct oral anticoagulant (DOAC) for the prevention of cancer-associated thrombosis in the United States","volume":"126","author":"Li","year":"2020","journal-title":"Cancer"},{"issue":"20","key":"10.1016\/j.ygyno.2024.05.028_bb0185","doi-asserted-by":"crossref","first-page":"5215","DOI":"10.1182\/bloodadvances.2020003115","article-title":"Primary thromboprophylaxis in ambulatory cancer patients with a high Khorana score: a systematic review and meta-analysis","volume":"4","author":"Bosch","year":"2020","journal-title":"Blood Adv."},{"issue":"02","key":"10.1016\/j.ygyno.2024.05.028_bb0190","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1160\/TH16-08-0615","article-title":"Cancer-associated venous thromboembolism: burden, mechanisms, and management","volume":"117","author":"Ay","year":"2017","journal-title":"Thromb. Haemost."},{"issue":"1","key":"10.1016\/j.ygyno.2024.05.028_bb0195","doi-asserted-by":"crossref","first-page":"9519","DOI":"10.1038\/s41598-023-36161-w","article-title":"Thrombogenesis-associated genetic determinants as predictors of thromboembolism and prognosis in cervical cancer","volume":"13","author":"Neto","year":"2023","journal-title":"Sci. Rep."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002609?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825824002609?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,2,4]],"date-time":"2025-02-04T21:23:14Z","timestamp":1738704194000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825824002609"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,9]]},"references-count":39,"alternative-id":["S0090825824002609"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.028","relation":{},"ISSN":["0090-8258"],"issn-type":[{"type":"print","value":"0090-8258"}],"subject":[],"published":{"date-parts":[[2024,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Predicting VTE and utility of thromboprophylaxis in metastatic and recurrent cervical cancer","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2024.05.028","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}